Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pain Syndromes

FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

Natalie Grover & Toni Clarke  |  June 8, 2016

(Reuters)—A U.S. Food and Drug Administration (FDA) advisory panel recommended approving Teva Pharmaceuticals Industries Ltd’s long-acting opioid painkiller, Vantrela ER, saying data showed it reduces pain and has some abuse-resistant properties. The drug is designed for use every 12 hours for the management of pain severe enough to require around-the-clock treatment in patients who have…

Lilly Says New Type of Pain Drug Could Reduce Need for Opioids

Ransdell Pierson  |  May 28, 2016

(Reuters)—Eli Lilly and Co. on Tuesday said it and partner Pfizer Inc. aim to seek approval by 2018 for a new type of pain drug that could be an alternative to opioids for osteoarthritis, chronic back pain and cancer pain. The Indianapolis drugmaker said tanezumab, given by injection every eight weeks, could be a far…

Practicing Mindfulness Can Help Alter Patients’ Experience With Chronic Rheumatic Diseases

Practicing Mindfulness Can Help Alter Patients’ Experience with Chronic Rheumatic Diseases

C. Ronald MacKenzie, MD  |  April 15, 2016

Mindfulness is a mental state achieved by focusing one’s awareness on the present moment, while acknowledging and non-judgmentally accepting one’s feelings, thoughts and bodily sensations. Known in Sanskrit as smrti, meaning “to remember,” in Pali, the language of early Buddhist scriptures, it is recognized by the word sati (mindfulness).1 Derived from ancient meditative Buddhist disciplines,…

A Long Way to Go: Treating Pain in Patients with Inflammation

Richard Quinn  |  April 15, 2016

Subjectivity and the differences in how patients with autoimmune and other diseases perceive pain make the study and treatment of pain difficult. But Yvonne Lee, MD, says future advances in neuroimaging may aid in the objective study of pain and innovative treatments…

Self-Reported Knee Instability After Surgery Linked to Pain & Limited Mobility

Arthritis Care & Research  |  April 5, 2016

Patients with osteoarthritis often consider total knee replacement surgery to resolve pain and increase mobility. However, a recent study found that self-reported knee instability and pain are prevalent in patients both before and after primary unilateral total knee replacement surgery. One-third of the study’s participants still had knee instability after surgery, experiencing knee buckling and shifting associated with pain and limited activity. Using physical performance measurements, researchers linked self-reported knee instability following surgery to pain and poor lower-extremity muscle strength…

Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Anne Harding  |  March 30, 2016

NEW YORK (Reuters Health)—Medical cannabis reduces chronic pain patients’ opioid use, while improving their quality of life, according to a new survey of Michigan cannabis dispensary patrons. “They report that when they make that switch they overall feel better,” Dr. Daniel J. Clauw of the University of Michigan, Ann Arbor, told Reuters Health in a…

Mind-Body Therapy Helps Ease Chronic Low Back Pain

Andrew M. Seaman  |  March 26, 2016

(Reuters Health)—Mind-based therapy programs may help ease chronic back pain, new research suggests. Patients who took part in such programs were more likely to have noticeable and lasting improvements in back pain than those who stuck to their usual routines, investigators found. Both of the approaches tested in the study—mindfulness-based stress reduction (MBSR) and cognitive…

Fibromyalgia & Bipolar Spectrum Disorder: A Shared Pathophysiology May Lead to Better Drug Targets

Lara C. Pullen, PhD  |  March 21, 2016

Patients suffering from fibromyalgia and those suffering from bipolar spectrum disorder experience similar symptoms. Research suggests that these diseases may share a pathophysiological process, particularly a similar impairment in the prefrontal-limbic networks of the brain. A new editorial addresses how a better understanding of the potential shared biological underpinning of these diseases could result in unique drug targets…

U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids

Ransdell Pierson  |  March 18, 2016

(Reuters)—Addressing a growing “epidemic” of opioid overdoses and abuse of the prescribed painkillers in the U.S., the Centers for Disease Control and Prevention on Tuesday released voluntary guidelines that instruct primary care doctors to sharply deter use of the medicines for chronic pain. “Overprescribing opioids, largely for chronic pain, is a key driver of America’s…

FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

Michele B. Kaufman, PharmD, BCGP  |  February 17, 2016

Recently, an FDA committee announced support for the approval of CT-P13, an infliximab biosimilar. The FDA has also fast tracked the development of a fibromyalgia treatment designed for multiple symptoms…

  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences